Procurement of parenterally administered drugs for the treatment of oncological diseases for 2027 and 2028

This tender focuses on the reliable supply of essential parenteral oncological drugs. Success hinges on demonstrating robust supply chain management, adherence to stringent quality standards, and competitive pricing. While social and environmental aspects are not explicitly mandated, demonstrating a commitment to patient access and ethical sourcing can provide a subtle advantage.

Uninterrupted and Reliable Supply of Critical Oncology Medications

Commitment to Quality and Patient Safety

Value for Money through Competitive Pricing and Efficient Operations

Provide detailed evidence of a resilient and secure supply chain, including inventory management, logistics, and contingency plans for disruptions. Showcase robust quality control measures, certifications (e.g., GMP), and pharmacovigilance systems. Reference 'Iepirkuma priekšmeta prasības, 1.versija' for specific technical requirements.

Develop a highly competitive pricing strategy that balances profitability with market competitiveness. Consider volume discounts or tiered pricing if applicable. Ensure the financial proposal is clear, transparent, and directly addresses the estimated value (if it becomes known) and the duration of the contract.

Meticulously review and adhere to all submission requirements outlined in 'Iepirkuma priekšmeta prasības, 1.versija' and 'Nolikums'. Ensure all mandatory exclusion grounds and eligibility criteria are addressed with supporting documentation. Double-check all forms and appendices, especially Appendix 1 from 'Nolikums'.

This document is central to understanding all selection criteria, technical, and financial proposal requirements. A deep dive is essential to ensure full compliance and identify any implicit expectations.

Given the nature of oncology drugs, demonstrating an exceptionally robust and reliable supply chain, coupled with stringent quality control, will be a key differentiator, even if not explicitly weighted.

Without explicit evaluation criteria, price is likely to be a significant factor. Offer a competitive price that reflects efficiency and long-term value, avoiding excessive fluctuations.

Ensure full understanding and compliance with all procedural aspects and specific requirements detailed in the 'Nolikums', particularly Appendix 1, as it forms part of the open tender.

Anticipate that other established pharmaceutical suppliers will bid. Focus on clear, concise, and compelling evidence of capability and value.

While not a formal requirement, framing the bid around ensuring consistent patient access to essential oncology treatments can resonate positively.

This tender for oncological drugs is generally well-structured with clear documentation, but lacks transparency regarding financial value and specific evaluation criteria. The process is largely compliant with e-procurement standards.

The tender adheres to open procedure, provides a CPV code, and has a reasonable submission deadline. No disputes are noted. The procedure appears compliant with general procurement regulations.

The title and description are clear. Key documents outlining requirements are referenced, though their full content is not immediately accessible without further steps. Evaluation criteria are not explicitly specified in the provided summary.

Basic information like title, reference, organization, and deadlines are present. Contract duration is specified. However, the estimated financial value is not disclosed, impacting overall completeness.

The tender utilizes e-procurement, which promotes fairness. However, the 'Restricted document access' flag raises concerns about full document accessibility for all potential bidders. Objective criteria are implied but not explicitly detailed.

The tender is designated as e-procurement, which is positive. However, the 'No e-submission' flag suggests potential limitations in the submission process. Financing information and contract start date are not explicitly detailed.

Key fields such as title, reference, organization, and deadlines are populated. There are no reported suspensions or disputes, and the dates appear logically sequenced.

The tender does not explicitly mention green procurement, social aspects, or innovation. It is not indicated as EU funded, suggesting a lack of specific sustainability focus.